彭安庆 , 郑敏娟 . 药物负荷超声心动图及新型腺苷类负荷药物的临床应用[J]. 中华医学超声杂志（电子版）, 2024 , 21(02) : 183 -186 . DOI: 10.3877/cma.j.issn.1672-6448.2024.02.014

1	中国心血管健康与疾病报告2021概要[J].中国循环杂志, 2022, 37(6): 553-578.

2	吴爵非, 吕创业, 唐颖, 等. 腺苷负荷心肌声学造影的临床应用[J/CD].中华医学超声杂志(电子版), 2019, 16(10): 723-726.

3	中华医学会超声医学分会超声心动图学组.负荷超声心动图规范化操作指南[J].中国医学影像技术, 2017, 33(4): 632-638.

4	林静茹, 吴伟春. 负荷超声心动图联合心肌应变技术在心脏疾病中的应用进展[J/CD].中华医学超声杂志(电子版), 2019, 16(9): 709-713.

5	张源祥, 邱银汝, 梁志尧, 等.多巴酚丁胺负荷超声造影诊断冠心病的初步研究[J/OL].中华医学超声杂志(电子版), 2020, 17(4): 327-334.

6	刘迪, 朱秋红, 刘涛生, 等. 双嘧达莫联合舒血宁治疗超溶栓时间窗急性脑梗死的临床疗效及凝血指标观察[J]. 中国现代应用药学, 2020, 37(10): 1214-1217.

7	Ji W, Tang X, Du W, et al. Optical/electrochemical methods for detecting mitochondrial energy metabolism [J].Chem Soc Rev, 2022, 51(1): 71-127.

8	Bertero E, Maack C. The partial adenosine A1 receptor agonist in patients with chronic heart failure and preserved ejection fraction (PANACHE) trial [J].Cardiovasc Res, 2019, 115(8): e71-e73.

9	Borea PA, Gessi S, Merighi S, et al. Pharmacology of adenosine receptors: the state of the art [J].Physiol Rev, 2018, 98(3): 1591-1625.

10	Burnstock G. Purinergic signaling in the cardiovascular system [J]. Circ Res, 2017, 120(1): 207-228.

11	中华医学会放射学分会心胸学组, 国家心血管病专业质控中心心血管影像质控专家工作组. 动态CT心肌灌注成像技术操作与图像分析中国专家共识 [J].中华放射学杂志, 2022, 56(12): 1289-1299.

12	Headrick JP, Peart JN, Reichelt ME, et al. Adenosine and its receptors in the heart: Regulation, retaliation and adaptation [J]. Biochim Biophysa Acta, 2011, 1808(5): 1413-1428.

13	Fayez AM, Zakaria S, Moustafa D. Alpha lipoic acid exerts antioxidant effect via Nrf2/HO-1 pathway activation and suppresses hepatic stellate cells activation induced by methotrexate in rats [J].Biomed Pharmacother, 2018, 105: 428-433.

14	吕创业, 张建琴, 唐颖, 等.腺苷负荷心肌声学造影在慢性冠脉综合征中的诊断价值[J].中国超声医学杂志, 2020, 36(9): 805-809.

15	张源祥, 邱银汝, 梁志尧, 等.三磷酸腺苷和多巴酚丁胺负荷超声造影在冠心病诊断中的对比研究[J/OL].中华医学超声杂志(电子版), 2020, 17(4): 335-340.

16	Cantoni V, Green R, Acampa W, et al. Diagnostic performance of myocardial perfusion imaging with conventional and CZT single-photon emission computed tomography in detecting coronary artery disease: A meta-analysis [J].J Nucl Cardiol, 2021, 28(2): 698-715.

17	Anand V, Kane GC, Lee AT, et al. Prognostic role of cardiac power in a large cohort of patients with normal ejection fraction referred for dobutamine stress echocardiography [J].J Am Soc Echocardiogr, 2022, 35(11): 1139-1145.e3.

18	Pellikka PA, Arruda-Olson A, Chaudhry FA, et al. Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: from the American Society of Echocardiography [J]. J Am Soc Echocardiogr, 2020, 33(1): 1-41.e48.

19	郁婷燕, 黄朝旭, 蒲朝霞, 等.斑点追踪技术评价慢性冠状动脉综合征微循环病变左心室收缩功能及ATP负荷的影响[J].中国医学影像学杂志, 2023, 31(5): 467-473.

20	Sidhu GS, Hendel RC. The evolution of the prognostic value of regadenoson SPECT myocardial perfusion imaging [J]. J Nucl Cardiol, 2021, 28(6): 2808-2811.

21	Steeds RP, Wheeler R, Bhattacharyya S, et al. Stress echocardiography in coronary artery disease: a practical guideline from the British Society of Echocardiography [J]. Echo Res Pract, 2019, 6(2): G17-G33.

22	Porter TR, Mulvagh SL, Abdelmoneim SS, et al. Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography Guidelines Update [J]. J Am Soc Echocardiogr, 2018, 31(3): 241-274.

23

Kunadian V, Chieffo A, Camici PG, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group [J]. Eur Heart J, 2020, 41(37): 3504-3520.

24	Brink HL, Dickerson JA, Stephens JA, et al. Comparison of the safety of adenosine and regadenoson in patients undergoing outpatient cardiac stress testing [J]. Pharmacotherapy, 2015, 35(12): 1117-1123.

25	Andrikopoulou E, Hage FG. Adverse effects associated with regadenoson myocardial perfusion imaging [J]. J Nucl Cardiol, 2018, 25(5): 1724-1731.

26	Romero Castro M, Fernandez Galindo M, Garcia Robles JA, et al. Regadenoson stress echocardiography: a road ahead [M].  Oxford: Oxford University Press, 2022.

27	Iglesias-Garriz I, Vara-Manso J, Sevilla A, et al. Diagnostic accuracy of regadenoson stress echocardiography: concordance with gated-spect myocardial perfusion imaging [J]. Int J Cardiovasc Imaging, 2021, 37(2): 509-515.

28	Shaikh K, Wang DD, Saad H, et al. Feasibility, safety and accuracy of regadenoson-atropine (REGAT) stress echocardiography for the diagnosis of coronary artery disease: an angiographic correlative study [J]. Int J Cardiovasc Imaging, 2014, 30(3): 515-522.

29	Porter TR, Adolphson M, High RR, et al. Rapid detection of coronary artery stenoses with real-time perfusion echocardiography during regadenoson stress [J]. Circ Cardiovasc Imaging, 2011, 4(6): 628-635.

30	Sinha A, Dutta U, Demir OM, et al. Rethinking false positive exercise electrocardiographic stress tests by assessing coronary microvascular function [J].J Am Coll Cardiol, 2024, 83(2): 291-299.

31	李牧蔚, Wende C. 冠状动脉微循环功能障碍 [J]. 中华实用诊断与治疗杂志, 2019, 33(9): 838-842.

32	中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. ST段抬高型心肌梗死患者急诊PCI微循环保护策略中国专家共识 [J]. 中华心血管病杂志, 2022, 50(3): 221-230.

33	中华医学会心血管病学分会基础研究学组, 中华医学会心血管病学分会介入心脏病学组, 中华医学会心血管病学分会女性心脏健康学组, 等. 冠状动脉微血管疾病诊断和治疗的中国专家共识 [J]. 中国循环杂志, 2017, 32(5): 421-430.

34	Roczniak J, Bączalska J, Kanclerz G, et al. Comparison of regadenoson and dipyridamole safety profiles during stress myocardial perfusion imaging [J]. Mol Imaging Radionucl Ther, 2023, 32(2): 131-137.

35	Monmeneu Menadas JV, García Gonzalez MP, Lopez-Lereu MP, et al. Safety and tolerability of regadenoson in comparison with adenosine stress cardiovascular magnetic resonance: Data from a multicentre prospective registry [J]. Int J Cardiovasc Imaging, 2022, 38(1): 195-209.

36	Hwang D, Park SH, Koo BK. Ischemia with nonobstructive coronary artery disease: concept, assessment, and management [J]. JACC Asia, 2023, 3(2): 169-184.

37	Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic criteria for microvascular angina [J]. Int J Cardiol, 2018, 250: 16-20.

38	Chen W, Ni M, Huang H, et al. Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases (2023 Edition) [J]. MedComm (2020), 2023, 4(6): e438.

39	中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 缺血伴非阻塞性冠状动脉疾病诊断及管理中国专家共识 [J].中华心血管病杂志, 2022, 50(12): 1148-1160.

40	中国超声心动图学会, 中华医学会超声医学分会浅表组织和血管学组, 中国医药教育学会超声医学专业委员会. 慢性冠状动脉综合征负荷超声心动图检查临床实践指南(2023版) [J].中华超声影像学杂志, 2023, 32(11): 921-945.

41	Schroder J, Prescott E. Doppler echocardiography assessment of coronary microvascular function in patients with angina and no obstructive coronary artery disease [J]. Front Cardiovasc Med, 2021, 8: 723542.

42	Schroder J, Michelsen MM, Mygind ND, et al. Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study [J]. Eur Heart J, 2021, 42(3): 228-239.

43	Elkholy KO, Hegazy O, Okunade A, et al. Regadenoson stress testing: a comprehensive review with a focused update[J]. Cureus, 2021, 13(1): e12940.

44	Shakowski C, Pham VA, Raines J, et al. Safety and efficacy of IV theophylline for regadenoson-associated side effect reversal[J]. J Nucl Cardiol, 2023, 30(2): 585-589.